Results 211 to 220 of about 163,967 (239)

Correction to:Efficacy and safety of surufatinib in the treatment of thymic neuroendocrine tumors: a 102-case retrospective study. [PDF]

Oncologist
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification

Modern Pathology, 2021
The classification of adenohypophysial neoplasms as "pituitary neuroendocrine tumors" (PitNETs) was proposed in 2017 to reflect their characteristics as epithelial neuroendocrine neoplasms with a spectrum of clinical behaviors ranging from small indolent lesions to large, locally invasive, unresectable tumors.
Sylvia L. Asa, Ozgur Mete, Michael D. Cusimano, Ian E. McCutcheon, Arie Perry, Shozo Yamada, Hiroshi Nishioka, Olivera Casar-Borota, Silvia Uccella, Stefano La Rosa, Ashley B. Grossman, Shereen Ezzat, null International Pituitary Pathology, Sofia Asioli, Süheyla Uyar Bozkurt, Nil Comunoglu, Giulia Cossu, Peter Earls, Nuperi Gazioglu, Richard A. Hickman, Hidetoshi Ikeda, Emilija Manojlovic-Gacic, Mahmoud Messerer, Buge Öz, Sara Pakbaz, Federico Roncaroli, Wolfgang Saeger, John Turchini, Sema Yarman   +28 more
openaire   +3 more sources

Neuroendocrine Tumors

Gastroenterology Clinics of North America, 2016
Neuroendocrine tumors are increasingly diagnosed, either incidentally as part of screening processes, or for symptoms, which have commonly been mistaken for other disorders initially. The diagnostic workup to characterize tumor behaviour and prognosis focuses on histologic, anatomic, and functional imaging assessments. Several therapeutic options exist
Basuroy, Ron, Srirajaskanthan, Raj, Ramage, John K   +2 more
openaire   +4 more sources

Thymic Neuroendocrine Tumors

Thoracic Surgery Clinics, 2014
Thymic neuroendocrine tumors are rare and account for approximately 2% to 5% of all thymic tumors. Despite the suggestion of benign behavior implied by their name, thymic carcinoids have been noted to present a more aggressive biologic behavior than their counterparts in other sites.
Lausi P. O., Refai M., Filosso P. L., Ruffini E., Oliaro A., Guerrera F., Brunelli A.   +6 more
openaire   +4 more sources

Theragnostic in neuroendocrine tumors

The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022
In the last few decades, the incidence and prevalence of neuroendocrine tumors has been increasing. The theragnostic approach, that allows the diagnosis and treatment of different neoplasms with the same ligand, is a typical nuclear medicine tool. Applied for years, is also pivotal in neuroendocrine tumors (NETs) where it has improved the diagnostic ...
Marini I., Sansovini M., Bongiovanni A., Nicolini S., Grassi I., Ranallo N., Monti M., Iorio V. D. I., Germano L., Caroli P., Sarnelli A., Paganelli G., Severi S.   +12 more
openaire   +2 more sources

Neuroendocrine tumors of the pancreas

Surgical Endoscopy, 2003
The benefits of associating magnetic resonance imaging (MRI) and laparoscopy for localizing and treating neuroendocrine pancreatic tumors (NEPTs) have been poorly documented.In a retrospective study, eight patients with a mean age of 48 years were operated on for a NEPT. MRI was used to localize the lesions. In all patients a laparoscopic resection was
Van Nieuwenhove, Yves, Vandaele, Shiran, Op De Beeck, Bart, Delvaux, Georges   +3 more
openaire   +4 more sources